Glooko and Hedia announced today that launched their interoperable solution for advanced bolus insulin dosing support.

"We believe that 2025 will be a pivotal year for SELLAS as we continue to advance our clinical stage portfolio of novel therapeutics for hematologic malignancies,” said Angelos ...

New integration delivers personalised insulin dosing advice, improving care for people with diabetes and enhancing healthcare provider insights. COPENHAGEN, Denmark and PALO ALTO, Calif.

Glooko’s integration of Hedia’s diabetes tech aims to improve care for patients and enhance healthcare provider insights.

Glooko, Inc. and Hedia, today announced the launch of their interoperable solution, which combines connected care, remote ...

New integration delivers personalised insulin dosing advice, improving care for people with diabetes and enhancing healthcare provider insights. Glooko, Inc. and Hedia today announced the launch ...